LGND up +3.50% percent Today $LGND High is at 57.76 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 12:42 PM

LGND up +3.50% percent Today $LGND High is at 57.76 and the Low 55.60 with current volume of 160,705.

Recent News posted below.

Ligand Pharmaceuticals Inc LGND other info.
http://investorshangout.com/Ligand-Pharmaceut...GND-54621/

LGND Ligand Pharmaceuticals Inc Recent Headline News

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 18 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.26 (+2.58)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.57 (+0.76), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.41 (-0.73)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.26 (+2.58)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.26 (+2.58)

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.81 (-1.06), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)

Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT

PFE: 30.20 (unch), AZN: 74.23 (+1.02), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)

Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT

LGND: 58.26 (+2.58)

Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT

LGND: 58.26 (+2.58)

Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT

LGND: 58.26 (+2.58)

Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.26 (+2.58)

Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT

LGND: 58.26 (+2.58)

Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.26 (+2.58)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT

ROP: 157.40 (-1.13), SIR: 24.19 (-0.05), VNDA: 12.83 (+0.67), STX: 61.65 (-0.12), NMM: 13.64 (unch), LGND: 58.26 (+2.58), PDS: 7.82 (+0.06), TREX: 44.00 (-0.01), EXAS: 22.59 (-0.01), AWI: 49.17 (unch), EDR: 11.58 (-0.04), HUN: 24.96 (+0.03), TEN: 53.19 (-0.25), AGN: 195.84 (+0.60), ONB: 14.85 (-0.06), STNG: 8.75 (+0.11), MRK: 59.58 (+0.77), BEN: 56.75 (+0.18)

Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.54 (+0.60), PFE: 30.20 (unch), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)

Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)

Ligand Pharmaceuticals Inc. (LGND) Stock Research Links

LGND Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NSSF Battles NM's Unconstitutional Gun Law in Court

Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

Burger King Unveils Hello Kitty® Partnership Frenzy

Burger King's Hello Kitty® Move: Fad or Brilliant? Few things scream nostalgia like Hello Kitty® and a Burger King kids' meal. It's the kind of combo that makes you wonder if we're simply riding a wave of kawaii nostalgia or if this is a masterstroke tapping into a multi-generational goldmine. What's in the Box? Burger King isn't playing around. Starting October 20,...

Hughes Brothers Under Scrutiny: Legal Stakes Rise

Legal Spotlight on Hughes Brothers Construction Inc. Talk about a shakeup. Hughes Brothers Construction Inc. finds itself under the sharp scrutiny of a class action magnifying glass. We're not talking some small-time whispers either; Monteverde & Associates is the name here—top dogs in the securities class action world. This crew's headquartered in the iconic Empire...

Software Tax Hits Enterprises: Costly Control Concerns

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

Fitch Ratings Applauds Ecopetrol's Financial Sturdiness

Ecopetrol: A Rock in Turbulent Waters If you’re looking for a boulder in a sea of pebbles, Ecopetrol’s got the heft. When Fitch Ratings gives a thumbs-up, you best believe they mean it. On October 20, 2026, the rating agency confirmed Ecopetrol’s global credit rating at BB, with a stable outlook, but it’s how they got there that counts. Their standalone credit...

Parents as Teachers Podcast: Anthem Awards Finalist

Celebrating Impact Through Parenthood Narratives Blending heartfelt stories with educational insights, the Parents as Teachers Podcast stands tall as a Finalist in two categories of the 6th Annual Anthem Awards. Recognizing achievements in Content & Media for both Education, Art & Culture and Health, this nod acknowledges the profound impact being made on family...

Ecore Athletic Boosts American Conference Sports Venues

Eco-Friendly Floors or Marketing Fluff? On the surface, Ecore Athletic inking a deal with the American Conference seems like another run-of-the-mill partnership. But dig a little deeper, and it’s not just hardwood and rubber underfoot. There’s some serious ambition here, along with a dash of circularity PR. A Partnership with Broader Impact The nitty-gritty of the...

Norwegian Bella™: A New Era in Luxury Cruising

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

Shadeform's Spot: Monetizing Idle GPU Resources

Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...